Ligand Pharmaceuticals Inc. reports developments in its biopharmaceutical royalty aggregation and technology-licensing business. The company partners with pharmaceutical and biotechnology companies, funds late-stage clinical development programs in exchange for long-term economic interests, and manages royalty interests across development- and commercial-stage therapeutic assets.
Recurring LGND news includes operating and financial results, royalty revenue drivers, material agreements, capital-structure updates, and partner clinical or regulatory events tied to products in the portfolio. Company updates also cover proprietary technologies such as Captisol® and NITRICIL™, business-development activity, and portfolio assets such as FILSPARI® where Ligand has an economic interest.
Ligand (Nasdaq: LGND) priced an upsized private offering of $625 million aggregate principal amount of 0.0% convertible senior notes due 2031, with an option for an additional $75 million.
Net proceeds of about $605.3 million will fund convertible note hedges, a $60 million share repurchase of 228,859 shares at $262.17, and general corporate purposes, including its previously announced Xoma Royalty Corporation acquisition. The initial conversion price is approximately $334.27 per share, a 27.5% premium to the last closing price, and related warrant transactions carry a $524.34 strike price, 100% above that close.
Ligand (Nasdaq: LGND) plans a private offering of $550 million convertible senior notes due September 15, 2031, with an option for an additional $82.5 million. The notes are senior unsecured, pay semiannual interest starting March 15, 2027, and are convertible into cash and/or stock.
Ligand expects to use proceeds for convertible note hedge and warrant transactions, up to $75 million in share repurchases, and general corporate purposes, including its agreement to acquire Xoma Royalty Corporation. Hedge transactions aim to reduce conversion-related dilution, while associated warrants may be dilutive above their strike price.
Ligand (Nasdaq: LGND) will host a 2026 Investor Day in New York City on December 8, 2026, at 10:30 a.m. Eastern time at the Harvard Club.
Presentations from senior management will cover strategy, recent investment activity, the royalty portfolio, and long-term financial outlook, with a live webcast on the Investor Relations site.
Ligand (Nasdaq: LGND) announced participation in two June 2026 investor conferences. At the Stifel 2026 Boston Cross Sector 1x1 Conference, management will hold one-on-one investor meetings on June 3, 2026 in Boston.
At the Goldman Sachs 47th Annual Global Healthcare Conference, management will host a fireside chat on June 10, 2026 at 10:00 a.m. ET in Miami, followed by one-on-one meetings.
Ligand (Nasdaq: LGND) reported Q1 2026 results with total revenue $51.7M and royalty revenue $43.0M (up 56% YoY). GAAP net loss was $13.3M; adjusted net income was $34.6M or $1.63 per diluted share. Cash and short-term investments were $779.4M at March 31, 2026. Ligand reaffirmed 2026 guidance: adjusted EPS ~$8.50–$9.50 and royalty revenue $225M–$250M, reflecting anticipated partial-year contribution from the pending XOMA acquisition, expected to close in Q3 2026, subject to customary conditions.
Ligand (Nasdaq: LGND) will have senior management participate in multiple investor conferences in May 2026, including virtual and in-person events. Management will give fireside chats and host one-on-one meetings at H.C. Wainwright, Bank of America, CJS Securities, RBC, Craig-Hallum, Benchmark, and others.
Investors seeking one-on-one meetings should contact their conference or broker representative to arrange sessions.
Ligand (Nasdaq: LGND) agreed to acquire XOMA Royalty for $39.00 per share, ~$739 million equity value, plus one non-transferable CVR per share tied to ongoing litigation. The deal expands Ligand's royalty portfolio to >200 assets, adds seven marketed products and is expected to close in Q3 2026.
Ligand raised 2026 guidance: revenue to $270–$310M, royalties to $225–$250M, and adjusted EPS to $8.50–$9.50; Ligand expects the transaction to be accretive by $1.50 to adjusted EPS in 2027.
Ligand (Nasdaq: LGND) will report first quarter 2026 financial results on Thursday, May 7, 2026. A conference call will begin at 8:30 a.m. Eastern to discuss results and provide a business update. Live webcast and replay will be available via the company’s webcast link.
Dial-in details include U.S. local, toll-free and international numbers with Meeting ID 304603090.
Ligand (Nasdaq: LGND) said partner Travere Therapeutics received full FDA approval on April 14, 2026 for FILSPARI (sparsentan) to reduce proteinuria in adults and children aged 8+ with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. Ligand is entitled to a 9% royalty on worldwide net sales. In Travere’s Phase 3 DUPLEX trial, FILSPARI cut proteinuria by 48% vs 27% for irbesartan in non‑nephrotic patients at Week 108 and showed a 1.1 mL/min/1.73 m2 eGFR benefit.
Ligand (Nasdaq: LGND) on March 26, 2026 announced senior hires to expand its investments and business development team. The company named Peter Renehan, MD and Lee Brown as Vice Presidents of Investments and Business Development and promoted Lauren Hay to Vice President of Portfolio Strategy and Investments.
All three will focus on sourcing and executing royalty financing opportunities and managing Ligand’s existing portfolio, reporting to Paul Hadden and supporting long‑term value creation for shareholders.